Evolution of BCL-2/IgH hybrid gene RNA expression during treatment of T(14;18)-bearing follicular lymphomas by Soubeyran, P et al.
Follicular lymphoma (FL) is a well-defined entity among non-
Hodgkin’s lymphoma (NHL) and is associated with the t(14;18)
that rearranges the bcl-2 gene with the immunoglobulin heavy-
chain gene (IgH) (Cleary et al, 1986; Weiss et al, 1987). The
hybrid gene, called bcl-2/IgH, produces hybrid mRNA and finally
high constitutive levels of the normal bcl-2 protein (Tsujimoto and
Croce, 1986). Consequently, the normal function of the bcl-2 gene
should account for the behaviour of these tumours.
Indeed, bcl-2 blocks programmed cell death and immortalizes
t(14;18)-bearing cells (Hockenbery et al, 1990), thus representing
the first step before malignant transformation. It is probably
responsible for the high rate of cells that remain in the G0 phase of
the cell cycle (Linette et al, 1996; Mazel et al, 1996; O’Reilly et al,
1996; Vairo et al, 1996), hence explaining the slow growth pattern.
Above all, recent studies have renewed the interest for bcl-2 while
demonstrating its involvement in drug resistance (Alnemri et al,
1992; Kamesaki et al, 1993; Lotem and Sachs, 1993; Miyashita
and Reed, 1993), which possibly accounts for the well-
documented inability of conventional chemotherapy to cure
disseminated disease. These results and in vitro studies that
have demonstrated the possibility of reversal of bcl-2-induced
resistance (Kitada et al, 1994; Reed et al, 1994; Keith et al, 1995)
led us to study this problem in the specific context of FL.
We recently demonstrated the absence of bcl-2/IgH expression
in t(14;18)-bearing cells circulating in patients with FL in
complete remission (CR) (Soubeyran et al, 1993), suggesting that
treatment may lead to bcl-2/IgH down-regulation. Consequently,
we decided to explore this possible relationship between treatment
and bcl-2/IgH down-regulation and to further investigate whether
it could be related to treatment response and outcome of t(14;18)-
bearing FL. We used our reverse transcription polymerase chain
reaction (RT-PCR) technique to detect bcl-2/IgH RNAs
(Soubeyran et al, 1993) in peripheral blood of FL patients.
MATERIALS AND METHODS
Patients
Patients selected in this study presented with a t(14;18)-bearing
lymphoma as demonstrated by PCR performed on a representative
lymph node biopsy. Pretreatment peripheral blood and bone
marrow were not accepted as a valid source to account for the risk
of tumour-unrelated benign t(14;18) clones (Limpens et al, 1991;
Aster et al, 1992; Ohshima et al, 1993; Corbally et al, 1994; Liu et
al, 1994; Bell et al, 1995; Ji et al, 1995; Limpens et al, 1995;
Dolken et al, 1996; Fuscoe et al, 1996). Furthermore, although
informed consent was requested, no sample was collected only for
the study purpose. Consequently, there was no sample collection if
no other blood analysis was needed. Finally, results were not made
available to the physician during the patient’s treatment.
During the study period (March 1992 to March 1997), 118
patients with FL tumours were treated either initially or at relapse
at the Institut Bergonié. Frozen tumours were available in 62 of
them and 36 were t(14;18)-bearing tumours (MBR breakpoints) as
demonstrated by PCR analysis (Soubeyran et al, 1993). In all, 25
patients were considered for this study and are described in Table
Evolution of BCL-2/IgH hybrid gene RNA expression
during treatment of T(14;18)-bearing follicular
lymphomas
P Soubeyran1, I Hostein1, M Debled2, H Eghbali2, I Soubeyran3, F Bonichon4, T Astier-Gin5 and B Hœrni2
Departments of 1Molecular Oncology, 2Haematology, 3Pathology and 4Statistics, Institut Bergonié, Regional Cancer Center, 180 rue de Saint-Genès,
33076 Bordeaux Cedex, France; 5Unité INSERM 328, 33076 Bordeaux Cedex, France
Summary Bcl-2, the gene over-expressed in follicular lymphomas (FL), is able to block chemotherapy-induced apoptosis. Consequently, we
wondered whether bcl-2/IgH expression variations during treatment of FL could predict the outcome of patients with t(14;18)-bearing FL. For
this purpose, we used a reverse transcription polymerase chain reaction (RT-PCR) assay to analyse 180 serial peripheral blood samples
(PBS) during 34 treatment phases in 25 patients with t(14;18)-bearing FL. In all patients but two, bcl-2/IgH gene expression was
demonstrated in pre-treatment samples. During 16 out of the 34 treatment phases (47%), bcl-2/IgH expression became negative: all but one
were responders to chemotherapy. This conversion was transient in six cases. In 18 treatment phases, bcl2/IgH expression remained
detectable: eight were clinically considered as treatment failures, while eight others achieved PR and two achieved CR. We observed a
significant correlation between treatment response and RNA PCR results (P = 0.002). Three-year overall survival of patients with stable
bcl2/IgH-negative conversion was 100% compared to 54% for the remaining patients (P = 0.069); 3-year freedom from progression was
respectively 87.5% and 13% (P = 0.005). These results indicate a correlation between bcl-2/IgH expression variations and both clinical
response and outcome. Whether this might predict disease outcome early remains to be confirmed. © 1999 Cancer Research Campaign
Keywords: non-Hodgkin’s lymphoma; residual disease; t(14;18); bcl-2; chemotherapy
860
British Journal of Cancer (1999) 81(5), 860–869
© 1999 Cancer Research Campaign
Article no. bjoc.1999.0777
Received 7 October 1998
Revised 12 April 1999
Accepted 22 April 1999
Correspondence to: P SoubeyranResidual disease in follicular lymphomas 861
British Journal of Cancer (1999) 81(5), 860–869 © 1999 Cancer Research Campaign
1. Histological diagnosis was confirmed as centroblastic-centro-
cytic lymphoma according to the Kiel classification (Lennert and
Feller, 1992), and as follicle centre lymphoma according to the
Revised European American Lymphoma (REAL) classification
(Harris et al, 1994). Localized stages were treated by involved
field irradiation either alone or combined with induction
chemotherapy (CVP regimen) (Soubeyran et al, 1988), or low-
dose total body irradiation as part of a prospective phase II trial
(Richaud et al, 1998). After an eventual wait-and-see period,
advanced stages were treated with different chemotherapies
(Chauvergne et al, 1977; Bonadonna et al, 1985; Soubeyran et al,
1991) including continuous oral treatment with cyclophosphamide
(100 mg per day) or chlorambucil (4 mg per day), CVP
(cyclophosphamide 750 mg m–2 day 1, vincristine 1.4 mg m–2 day
1, prednisone 40 mg m–2 days 1–7), fludarabine (25 mg m–2 days
1–5), CEP (carmustine 100 mg m–2 day 1, etoposide 100 mg m–2
days 1–5, prednimustine 80 mg m–2 days 1–5) or teniposide
(100 mg m–2 weekly). One patient received anti-CD52 monoclonal
antibody therapy as part of a phase II study. Six patients had
samples collected and analysed during successive treatment
phases, allowing for analysis of 34 treatment phases in 25 patients.
Methods
High molecular weight DNA and total cellular RNA were simulta-
neously extracted from frozen tumours with guanidine thio-
cyanate, caesium chloride and ultracentrifugation after grinding of
the tumour in liquid nitrogen as previously described (Sambrook
et al, 1989).
Peripheral mononuclear cells from peripheral blood samples
(PBS) were separated on ficoll hypaque gradient. Then, nucleic
acids were simultaneously extracted with the same method.
The PCR detection method of bcl-2/IgH DNA and transcripts
have already been described (Soubeyran et al, 1993). We restricted
the analysis to t(14;18) with breakpoints in the major breakpoint
clustering region (MBR) using mbr3 and JH19 primers
(Soubeyran et al, 1993) (Table 2).
PCR amplification of 1 mg DNA of each sample was performed
in a total reaction volume of 50 ml (10 mM Tris–HCl pH 8.3,
50 mM potassium chloride (KCl), 2 mM magnesium chloride
(MgCl2), 200 mM dNTP each, primers 30 pmol each) as follows:
hot-start PCR with a 94°C 5 min first step, then addition of one
(tumour samples) or two units (PBS) of Taq polymerase (Perkin-
Elmer Applied Biosystems Division, Foster City, CA, USA)
followed by 35 (tumour samples) or 45 cycles (PBS) of the usual
three phases (94°C denaturation step for 30 s, 55°C annealing step
for 15 s and 72°C extension step for 45 s) in a thermal cycler
(Perkin-Elmer Applied Biosystems Division).
Fifteen per cent of the PCR products were size-fractionated
in a 2% NuSieve gel (FMC Bioproducts, Rockland, ME, USA),
transferred to a Hybond N+ nylon membrane (Amersham,
Buckinghamshire, UK), then hybridized with a 3¢-end radio-
labelled oligonucleotide probe 18q21 (Soubeyran et al, 1993)
(Table 2) at 42°C overnight. Washing was carried out successively
in 2 sodium–saline citrate (SSC)–0.1% sodium dodecyl sulphate
(SDS) at room temperature, then 0.1 SSC–0.1% SDS at 50°C.
Autoradiography was performed against a single intensifying
screen at room temperature from one to 24 h.
The PCR sensitivity range was regularly monitored by dilution
assays (Soubeyran et al, 1993). Furthermore, a highly diluted 10–4
positive control was inserted into each PCR assay to ensure that
PCR could detect down to this level (Soubeyran et al, 1993).
Quality of DNA samples was confirmed by c-raf-1 amplification
at the DNA level.
Table 1 Patient characteristics
25 patients
Age Median (range) 46 (31–78)
Centroblastic-centrocytic Follicular 17 68%
(Kiel classification) Follicular and diffuse 3 12%
Diffuse 1 4%
With histologic transformation 4 16%
Follicle centre lymphoma, follicular Grade I 9 36%
(REAL classification) Grade II 8 32%
Grade III 3 12%
Diffuse 1 4%
With histologic transformation 4 16%
Stage I–II 7 28%
III–IV 18 72%
Performance status (WHO scale) 0–1 20 80%
2–4 5 20%
Bone marrow involvement Yes 11 44%
No 10 40%
Missing 4 16%
LDH Abnormal 5 20%
Normal 17 68%
Missing 3 12%
Treatment phase Initial 12 48%
Relapse 13 52%
Table 2 Oligonucleotide primers and probe sequences
Mbr3 : 5¢ TTT GAC CTT TAG AGA GTT GCT TTA CG 3¢
JH19 : 5¢ ACC TGA GGA GAC GGT GAC C 3¢
18q21 probe : 5¢ CAC AGA CCC ACC CAG AGC CC 3¢
Raf 8  : 5¢ GAT GCA ATT CGA AGT CAC AGC G 3¢
Raf 9 : 5¢ TTT TCT CCT GGG TCC CAG ATA 3¢
Raf 9 probe : 5¢ GTC CAG TAG CCC CAA CAA TCT G 3¢862 P Soubeyran et al
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To confirm further its specificity and uniqueness, we sequenced
the PCR products obtained from the tumour DNA of the 15
patients. The sequencing reactions were performed directly from
PCR-amplified DNA obtained with the same primers but 3¢ tailed
with –21M13 and reverse M13 sequences respectively on mbr3
and JH19. The PCR product was first purified using columns
(Wizard PCR Preps resin DNA purification system®; Promega,
Madison, WI, USA) to eliminate residual primers. Then, the
sequence was performed according to the supplier’s method with
the ABI PRISM® Dye primer cycle sequencing kit and run on the
automated DNA sequencer ABI prism 377 (Perkin-Elmer Applied
Biosystems Division).
RNA samples were processed successively with DNAase I
treatment, reverse transcription and standard PCR. Five micro-
grams of RNA were first treated by DNAase I (RNAase-free) in a
total reaction volume of 25 ml: 50 mM Tris–HCl pH 8.3; 75 mM
KCl; 3 mM MgCl2; 1 mM dithiothreitol (DTT); 40 U RNasin
(Promega); 70 U DNAase I RNAase-free (Boehringer, Mannheim,
Germany). The reaction was incubated at 37°C for 1 h, then heated
at 95°C for 5 min and immediately cooled on ice.
Then, 3 mg of these DNAase-treated RNA were submitted to
reverse transcription. The reaction was performed in a total reac-
tion volume of 50 ml in the following conditions: 50 mM Tris–HCl
pH 8.3; 75 mM KCl; 3 mM MgCl2; 1 mM dNTP each, 400 nM
pd(N6) random hexamers (Life Technologies, Bethesda, MD,
USA), 2 mM DTT, 80 U RNasin (Promega) and 200 U Superscript
reverse transcriptase (Life Technologies). First, each sample
without enzymes was denatured at 65°C for 5 min, then cooled on
ice. Finally, enzymes and DTT were added and the reaction
pursued at 37°C overnight.
For each sample, 3 different PCR reactions were simultaneously
performed in three different tubes with the mbr3 and JH19
primers: 1 mg of DNA, cDNA generated from 1 mg of RNA using
random hexamers, 1 mg of RNA without reverse transcription (as
negative control to rule out DNA contamination still persisting
after DNAase I treatment).
Further controls of these successive reactions were added: c-raf-
1 gene amplification using raf8 and raf9 primers (as a control of
both DNAase I and reverse transcription steps) as described previ-
ously (Table 2) (Soubeyran et al, 1993), and usual negative (nega-
tive DNA and no template) and diluted positive controls (10–4 mg
of positive DNA diluted in 1 mg of negative DNA). Each sample
was analysed at least twice during different assays to ensure
reliability of the results.
Finally, each sample was considered bcl-2/IgH RNA-positive
(R+) only when the RNA control (without reverse transcription)
was negative. Conversely, a sample was considered bcl-2/IgH
RNA-negative (R–) only if the c-raf-1 RNA band was clearly
detectable on agarose gel after ethidium bromide visualization.
We followed the recommendations of Kwok and co-workers
(Kwok and Higuchi, 1989) concerning contamination control.
Furthermore, the t(14;18) model with variable breakpoints and,
consequently, variable PCR product lengths allowed for more reli-
ability in contamination detection. If contamination occurred in
any of the negative controls including RNA controls (without
reverse transcription), the whole experiment was discarded.
Table 3 Sequence of the breakpoints of each clone
MBR N segment JH segment PCR
breakpoint breakpoint product
positiona positionb size (bp)
1 3057 CCGACCCCTACCCT 2363 JH5 141
2 3115 GCGGCGGGGGCCCCAAGGTCGTCCAGCCGTCTCTGACATAGGACACACCGGCATGAACTAG 2951 JH6 205
3 3129 TGTCCTCGGGTCCGCA 2949 JH6 234
4 3058 GTCATGGGTATCCGTAGGGGCTGCTATCGGGCCCCATGGCTGGT 2358 JH5 172
5 3065 GGCCGGGACTCTGT 2363 JH5 149
6 3054 GATATTCC 2956 JH6 144
7 3117 ACCCCTCTTTGCCATCCT 2955 JH6 218
8 3109 GCCAACCTCGGGTGAT 2952 JH6 211
9 3112 TGCGCCT 2952 JH6 205
10 3053 CCCCATGACCAACAAC 2950 JH6 157
11 3168 GACGCGGGATA 2953 JH6 264
12 3110 CCGCGAGCAGAGTGTGGT 2359 JH5 198
13 3165 CGCAAGGATCCGGGCTTGATG 2961 JH6 263
14 3115 ATCACCCTC 2963 JH6 199
15 3042 CTTATC 2960 JH6 126
16 3107 AAAGGA 1928 JH4 172
21 3052 GCTACGTGTGTGATGTGGGCAAAGAAAA 2955 JH6 163
23 3040 CCTTAC 2959 JH6 126
26 3110 ACGGGCAAGACCTAAGTTTCCTCAACTTGA 2951 JH6 228
27 3061 AACGCCGACCCGGAGACCCAAAATCGCCTGGAGGCAACTGGT 2357 JH5 171
31 3160 no N segment 2955 JH6 248
34 3164 GAGGCCGGA 2357 JH5 249
35 3056 TCCCACTTA 2950 JH6 153
36 3062 CCGGCTGAGACCCCTTAGACTACTTTGACTA 1924 JH4 154
38 3061 CTGATAAGA 1919 JH4 135
aAccording to Cleary published sequence (Cleary et al, 1986). bAccording to Ravetch published sequence (Ravetch et al, 1981).Residual disease in follicular lymphomas 863
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Statistical methods
The objective of the study was to predict response and outcome
based on circulating disease patterns observed during treatment.
Consequently, patterns of bcl-2/IgH RNA evolution were defined
according only to results observed till the end of treatment.
Delay to PBS collection was computed from treatment initia-
tion. Response was evaluated as usual with a minimum duration of
1 month to be acceptable (Miller et al, 1981). Relapse was consid-
ered as soon as the first symptom appeared. To study the relation-
ship between qualitative variables, we used the c2 test with Yates
correction for 2 ´ 2 tables. Survival curves were computed with
the Kaplan–Meier method and compared with the log-rank test.
Overall survival was computed from treatment initiation to death
or date last known alive. All causes of death were considered as
events. Freedom from progression was computed from treatment
initiation to progression or date last known free of disease, consid-
ering progression as an event. In patients with two or more succes-
sive treatment phases, survival curves were computed from
initiation of the first one.
The cut-off date for the last evaluation was 23 March 1998.
Median follow-up computed from treatment initiation to cut-off
date is 46.5 months (range 9–126 months).
RESULTS
Tumour and pretreatment PBS analysis
The t(14;18) tumour clone was clearly identified in all 25 cases.
The specificity and uniqueness of the PCR products was
confirmed through internal probe hybridization and sequencing of
the PCR products (Table 3).
Pretreatment bcl-2/IgH gene RNA expression in tumour cells
was confirmed in all but two cases, either in tumour (nine
patients), pretreatment blood sample (five patients) or both (nine
patients).
A total of 235 PBS were collected. Fifty-five PBS results (23%)
were not conclusive because of poor RNA quality, as demon-
strated by the absence of c-raf-1 RNA amplification. Thus, results
of 180 PBS were analysed, 51 collected before treatment initiation
and 129 during and after treatment. The median number of PBS
analysed per patient was seven (range 1–15). Results are outlined
in Tables 4–6. Representative samples are presented in Figure 1.
Analysis of PBS during treatment
The evolution of bcl2/IgH expression in t(14;18)-bearing cells was
investigated during treatment. There was a negative conversion of
bcl-2/IgH expression, as defined by complete disappearance of the
specific RNA signal in the circulating cells, during 16 treatment
phases (47%) in 14 patients. Three patterns of evolution were
observed: positive on each sample (18 treatment phases) and nega-
tive conversion (16 treatment phases) that could be transient (six
out of 16 phases) (Tables 4–6).
Bcl-2/IgH expression was always detectable in 18 treatment
phases (15 patients) (Tables 4 and 7): no treatment response was
observed in eight patients, while ten responded to chemotherapy,
eight of them partially. Among responding patients, six later
presented disease progression from 5 to 66 months after treatment
initiation (median 16 months), two relapsed after CR achievement
at 7 and 11 months and two patients remained in stable PR at 7.5
and 59 months.
In ten treatment phases (nine patients), negative conversion was
observed until the end of treatment (patient numbers 10–2, 11, 12,
DNA RNA control RNA DNA RNA control RNA DNA RNA control RNA DNA RNA control RNA
Tumour Pretreatment PBS During treatment
Patient
number
10
13
5
Figure 1 PCR amplification of bcl-2/IgH hybrid gene at both DNA and RNA levels. Hybridization results with 18q21 probe of tumour and PBS either before or
during treatment. Three lines per sample are represented: DNA for the PCR amplification of 1 mg of DNA; RNA for the PCR amplification of cDNA obtained after
reverse transcription of 1 mg of RNA; RNA control for the PCR amplification of 1 mg of RNA without reverse transcription864 P Soubeyran et al
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13, 14–2, 23 – Table 5; 10–1, 16, 21, 31 – Table 6); nine responses
were observed, including eight CR. The patient in PR relapsed at
35 months after treatment initiation, while the eight CR remained
disease-free 11–87 months after treatment initiation (median 38
months). The remaining treatment phase was associated with
progression: the phenotype D–R– was observed twice.
In six treatment phases (five patients), bcl-2/IgH became unde-
tectable transiently (one isolated R– PBS) then returned to positive
(patient numbers 7–2, 7–3, 8, 26, 27 – Table 5; 15 – Table 6): all
these responded to treatment. Four patients relapsed at 16–35
months after treatment initiation and the last remains in stable PR
at 24 months.
Correlation between bcl-2/IgH expression and
treatment response
In one patient with two successive treatments (No. 14), bcl-2/IgH
expression remained positive at a constant level during CVP
chemotherapy (Table 4). Progression occurred 3 months after CVP
discontinuation and fludarabine was given at this time. During this
Table 4 Bcl-2/IgH RNA expression during treatment. Patients who remained PBS bcl2/IgH RNA positive during treatment
Patient no. Stage Treatment Referencea Response Delayb (months) Pbs Status Evolutionc
1 III CEP D+R+(Tm) failure 1 D+R+ Death 7 m. later
2 II Irradiation D+R+(Tm) no change 0.5 D+R+
failure 1 D+R+ Death 1 m. later
3 IV MoAb D+(Tm) failure 1.5 D+R+ Death 2.5 m. later
4 III CVP D+R+(Tm) no change 6 D+R+
failure 6.5 Death 0.5 m. later
5 IV CPA D+R+(Tm) PR < 50% 5.5 D+R+
1st treatment phase CPA PR = 50% 22 D+R+
CPA PR = 50% 23 D+R+
CPA PR = 50% 23.5 D+R+
CPA failure 26 D+R+ Prog. 0 m.
5 IV Tenip. failure 2 D+R+ Death 0.5 m. later
2nd treatment phase
6 III CVP D+R+(Tm+pPBS) PR > 50% 1 D+R+
CVP PR > 50% 2 D+R+
CVP PR > 50% 3 D+R+
CVP PR > 50% 4 D–R+
failure 7 Death 2 m. later
7 II CVP D+R+(Tm+pPBS) PR = 50% 2 D+R+
1st treatment phase CVP CR 3 Relapse 4 m. later
9 III CHB D+(Tm) PR > 75% 55 D–R+
failure 66 Death 2 m. later
14 IV CVP D+R+(Tm+pPBS) PR > 50% 2 D+R+
1st treatment phase CVP PR > 50% 3 D+R+
CVP PR > 50% 8 D+R+ Prog. 3 m.
15 IV CVP D+R+(Tm+pPBS) no change 1 D+R+
1st treatment phase CVP no change 2 D+R+ Prog. 2 m.
15 III CEOP failure 4 D+R+ Death 3 m.
3rd treatment phase
26 III Fluda. MR 1 D+R+
2nd treatment phase Fluda. MR 3 D+R+
Fluda. MR 6 R+
progression 11 Death 9 m. later
34 IV CVP D+R+(Tm) PR 1 D+R+
CVP PR 3 D+R+
PR 3.5 D+R+
progression 5 Alive in prog. 11 m.
35 III CVP D+(Tm)D+R+(pPBS) PR 1 D+R+
CVP PR 2 D–R+ NED 5.5 m.
36 III CEOP D+(Tm)D+R+(pPBS) PR 0.7 D+R+
1st treatment phase CEOP PR 2 D+R+
CEOP PR 3 D+R+
CEOP CR 4 D+R+
No treatment CR 8 D+R+ Relapse 3 m. later
36 III CPA PR 6 D+R+
2nd treatment phase CPA PR 12 D+R+
CPA PR 16 D+R+
progression 16.5 Death 4 m. later
38 IV CVP D+R+(Tm+pPBS) PR 1 D+R+
uCR 41 D+R+ NED 18 m. later
aReference sample for bcl-2/IgH RNA expression. Tm: tumour – pPBS: pretreatment peripheral blood sample – D: t(14;18) PCR result at the DNA level – R:
t(14;18) PCR result at the RNA level. bDelay from treatment initiation to PBS collection. cEvolution since the last PBS collection. CVP: cyclophosphamide,
vincristine, prednisone; CEP: lomustine, etoposide, prednimustine; CPA: cyclophosphamide; CHB: chlorambucil; Tenip.: teniposide; Fluda.: fludarabine; MoAb:
monoclonal antibody; PR: partial response; CR: complete response; prog.: progression; AsPR: alive in stable PR; NED: no evidence of disease.Residual disease in follicular lymphomas 865
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second treatment phase, circulating t(14;18)-bearing cells rapidly
became bcl-2/IgH RNA negative and the patient achieved CR
(Table 5). He remained in persistent CR 26 months after second
treatment initiation.
We observed a significant relationship between treatment
response and RNA PCR results (Table 7) (P = 0.002). Among 13
complete responses, negative conversion of bcl-2/IgH expression
was observed in 11 cases during treatment. The only patient with
Table 5 Bcl-2/IgH RNA expression during treatment. Confirmed negative conversion during treatment: D+R– phenotype
Patient no. Stage Treatment Referencea Response Delayb (months) Pbs Status Evolutionc
7 IV CVP D+R+(pPBS) PR > 50% 1 D+R–
2nd treatment phase CVP PR > 75% 4 D+R+
7 CPA PR > 75% 10 D+R–
3rd treatment phase CPA PR > 75% 24 D+R+ AsPR
8 IV CVP D+(Tm) D+R+(pPBS) PR > 50% 1 D–R+
CVP PR > 50% 2 D–R+
CVP PR > 50% 3 D+R–
CVP PR > 50% 4 D–R+
CVP PR > 50% 6 D+R+
No treatment PR > 50% 7 D+R+
PR > 50% 9 D+R–
PR > 50% 11 D+R+
PR > 50% 18 D+R+
PR > 50% 27 D+R+ Relapse 3 m.
AsPR 2 m. later
10 CPA PR 2 D–R–
2nd treatment phase CPA PR 10 D+R–
CPA PR 10.5 D–R+
CPA PR 12.5 D–R–
CPA PR 19 D–R–
No treatment PR 28 D+R+ Relapse 7 m.
Death 9 m. later
11 IV Tenip. D+(Tm) PR > 50% 1 D+R+
Tenip. D+R+(pPBS) PR > 50% 14 D–R+
Tenip. PR > 50% 17 D+R+
Tenip. CR 24 D+R–
Tenip. CR 25 D+R–
Tenip. CR 28 D–R–
Tenip. CR 31 D+R–
No treatment CR 34 D+R+
CR 55 D–R–
CR 59 D–R– NED 28 m.
12 IV Fluda. D+R+(Tm+pPBS) PR > 75% 3 D+R+
Fluda. PR > 75% 4 D–R+
Fluda. CR 8 D–R–
No treatment CR 10 D+R–
CR 14 D+R–
CR 21 D–R+
CR 31 D+R– NED 4 m.
13 III CVP D+R+(Tm+pPBS) CR 0.7 D+R–
CVP CR 2 D–R–
No treatment CR 4 D+R–
CR 7 D+R–
CR 21 D–R– NED
14 IV Fluda. D+R+(Tm+pPBS) PR 1 D+R+
2nd treatment phase Fluda. CR 3 R+
Fluda. CR 4 D+R–
CR 22 D+R+ NED 4 m.
26 II CVP D+R+(Tm) PR > 50% 2 D+R–
1st treatment phase CVP CR 3 D+R+ Relapse III 13 m.
Death 25 m. later
27 II L85 D+(Tm) D+R+(pPBS) NE 2 days D+R+
L85 NE 4 days D+R–
L85 PR > 50% 1 D+R+
L85 PR > 50% 1.1 D+R+
CR 4 D–R–
CR 8 D–R–
CR 11 D+R+
18 D+R+ Relapse II 0 m.
NED 6 m.
See Table 4 legend for abbreviations and key; L85 = phase II trial in localized FL with induction low-dose total body irradiation followed by involved field
irradiation.866 P Soubeyran et al
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association of negative conversion and treatment failure (no. 10,
Table 6) had the D–R– phenotype.
Correlation between bcl-2/IgH expression and survival
To analyse overall survival and freedom from progression in these
patients, we considered only the first treatment phase of each
treatment. We designated two groups, i.e. patients with t(14;18)-
bearing tumour cells who either remained RNA-positive during
treatment or became transiently negative (R+ group) and those
whose tumour cells became RNA-negative till the end of treatment
(R– group). Median follow-up of these two groups is respectively
46.5 and 47 months (range 9–126 and 9–68 months). Three-year
overall survival of the R+ and R– groups was respectively 54%
and 100% (Figure 2, P = 0.069). Three-year freedom from
progression of the R+ and R– groups was respectively 13% and
87.5% (Figure 2, P = 0.005).
PBS analysis at the DNA level
The same patterns of evolution were observed at the DNA level:
always positive (21 treatment phases, 14 patients), and negative
conversion (13 treatment phases, 13 patients) that could be
transient (three treatment phases, three patients). No significant
relationship between DNA results and treatment response was
observed (Table 7, P = 0.27). We then analysed overall survival
and freedom from progression in these patients, considering only
PCR results obtained during the first treatment phase of each
patient. We designated two groups, i.e. patients with stable disap-
pearance of t(14;18)-bearing tumour cells during treatment (D–)
and those with either persistence or transient disappearance of
tumour cells (D+). No significant difference was observed
between the two groups for overall survival (Figure 3, P = 0.317).
Freedom from progression was significantly higher in the D–
group (Figure 3, P = 0.032).
DISCUSSION
Recently, it was demonstrated that, as expected, benign t(14;18)
clones can circulate in the blood of healthy patients (Bell et al,
1995; Ji et al, 1995; Limpens et al, 1995; Dolken et al, 1996;
Fuscoe et al, 1996). Moreover, multiple independent bcl-2/JH
translocations may simultaneously be present in the blood of
healthy donors (Ji et al, 1995; Limpens et al, 1995; Fuscoe et al,
1996). Although non-malignant, these circulating clones have
been suspected to be the first step that might later lead to FL occur-
rence in some, probably rare, cases (Liu et al, 1994; Ji et al, 1995).
Indeed, multiple circulating t(14;18)-bearing clones have been
observed in the blood of some FL patients (Price et al, 1991),
suggesting that malignant and benign t(14;18) clones co-exist.
Consequently, the t(14;18)-bearing clones detected in the blood of
FL patients could be either malignant or benign.
To pursue the study of residual disease in FL, methods must be
found to ensure that the detected clones are truly malignant. Two
Table 6 Bcl-2/IgH RNA expression during treatment. Unconfirmed negative conversion during treatment: D–R– phenotype
Patient no. Stage Treatment Referencea Response Delayb Pbs Status Evolutionc
10 III CVP D+R+(Tm) PR 0.7 m. D–R–
1st treatment phase CVP D–R+(pPBS) failure 1.5 m. D–R– Death 44 m. later
15 IV CPA PR < 50% 3 m. D+R+
2nd treatment phase CPA PR > 50% 11 m. D+R+
CPA PR > 50% 15 m. D–R–
CPA CR 21 m. D–R+
CPA CR 25 m. D+R+
CR 28 m. D–R– Relapse III 7 m.
16 II L85 D+R+(Tm+pPBS) CR 3 m. D+R+
L85 CR 5 m. R–
CR 9 m. D+R+
CR 17.5 m. R+
CR 41 m. D–R– NED 6 m.
21 I L85 D+R+(Tm) PR 2 d. D+R+
L85 PR 4 d. D+R+
L85 PR 1 m. D–R–
L85 PR 1.1 m. D–R–
CR 3 m. D–R+ NED 8 m.
23 IV Fluda. D+R+(Tm) PR 1 m. D–R–
Fluda. PR 3 m. D–R–
Fluda. CR 5 m. D–R–
CR 13 m. D–R+
CR 16 m. D–R–
CR 18 m. D–R–
CR 20 m. D–R–
CR 23 m. D+R–
CR 26 m. D–R+
CR 32 m. D–R– NED 13 m.
31 I Irradiation D+R+(Tm) CR 3 m. D–R–
CR 5 m. D–R–
CR 11 m. D+R+
CR 31 m. D+R+ NED 11 m.
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possible solutions might offset this problem. The first derives from
quantitative analyses performed in healthy patients (Liu et al,
1994; Ji et al, 1995; Dolken et al, 1996; Fuscoe et al, 1996). Such
studies have demonstrated that, in more than 90% of cases, the
amount of benign circulating cells is below the 10–5 sensitivity
limit of usual PCR assays. Furthermore, Dolken showed that the
amount of circulating cells was significantly lower in healthy
donors than in localized FL in long-term persistent CR (Dolken et
al, 1996). Therefore, PCR sensitivity must be controlled and kept
above the 10–5 threshold.
Another possibility is to identify the FL-related t(14;18) clone
in tumour material, so as to trace it further in the blood of FL
patients, while ignoring other unrelated clones. Although neither
of these methods absolutely eliminates the risk of misinterpreting
a benign clone as malignant, it is no longer possible to pursue
residual studies in the FL model without the mandatory use of both
of these methods. Therefore, we decided to select patients with
t(14;18)-bearing tumours that were clearly tumour-related as
demonstrated on a representative tumour sample, thus excluding
PBS and bone marrow as a source. Furthermore, we sequenced
each clone to ensure its uniqueness and precisely monitored the
PCR sensitivity range.
In a previous study, we designed an original PCR-based method
that allowed for the detection of bcl-2/IgH RNA in t(14;18)-
bearing cells (Soubeyran et al, 1993). Preliminary results showed
that bcl-2/IgH expression could not be detected in t(14;18)-bearing
circulating cells in a significant proportion of patients in CR.
However, no serial analysis was done to demonstrate the probable
relationship between bcl-2/IgH RNA disappearance and treatment.
In the present series, we analysed 180 PBS from 25 patients
during 34 treatment phases with previous pretreatment samples in
most of the cases. In 16 treatment phases (47%), we demonstrated
the disappearance of bcl-2/IgH RNAs, thus confirming the
expected influence of treatment on bcl-2/IgH gene expression.
The correlation of bcl-2/IgH expression evolution with response
to treatment was significant. Among the 13 patients who achieved
CR, only two were not associated with expression down-regula-
tion. Conversely, as expected, the absence of negative conversion
was associated with partial responses or even failures in most of
the cases (16 out of 18).
We further wondered whether these results could be related to
outcome and noted significant improvement of progression-free
survival in patients whose circulating cells remained bcl-2/IgH
RNA negative till the end of treatment. A similar tendency was
observed for overall survival, although it was not significant. The
only patient with adverse outcome in the R– group (no. 10, Table
6) had a D–R– phenotype, which does not strictly demonstrate that
circulating cells became bcl-2/IgH-negative: such cells could
remain undetectable, below the PCR sensitivity threshold, and
still be bcl-2/IgH RNA positive. Nonetheless, this patient was
considered as a negative conversion.
This relationship between down-regulation of bcl-2/IgH expres-
sion and outcome was expected because of the correlation
observed with response that is already known to have important
prognostic value (Soubeyran et al, 1991). However, this is another
Table 7 Relationship between treatment response and evolution of circulating disease patterns during treatment: bcl-2/IgH expression and standard DNA PCR
No complete response Complete response P-valuea
Remaining R+ during treatment 16 2
Negative conversion R+ to R– 5 11 0.002
Remaining D+ during treatment 15 6
Negative conversion D+ to D– 6 7 0.27
aChi-square with Yates correction.
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0 1 22 43 64 86 07 2
Months
Stable negative
conversion
group R–
No negative
conversion
or transient negative
conversion
P=0.69
group R+
A
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0 1 22 43 64 86 07 2
Months
Stable negative conversion
group R–
P=0.005
group R+
No negative conversion
or transient negative conversion
B
Figure 2 Patients with either persistence or transient disappearance of
bcl-2/IgH expression in circulating tumour cells during treatment (group R+)
and patients with stable disappearance of bcl-2/IgH expression in circulating
tumour cells during treatment (group R–); (A) overall survival; (B) freedom
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argument for the potential value of bcl-2/IgH expression down-
regulation in FL. This result points to new opportunities for FL
treatment. Indeed, bcl-2 down-regulation might not only be a tool
to assess early the potential value of a new treatment approach but
also could represent an aspect of future treatment strategies.
Our results are further corroborated by recent knowledge on the
ability of bcl-2 to block programmed cell death (Hockenbery et al,
1990) and consequently chemotherapy-induced apoptosis in
cancer cells. Since Miyashita’s early results (Miyashita and Reed,
1992, 1993), many authors have confirmed the importance of bcl-
2 in drug resistance (Alnemri et al, 1992; Kamesaki et al, 1993;
Lotem and Sachs, 1993) and later, the possibility to reverse this
phenomenon by antisense oligonucleotides directed against bcl-2
mRNA (Kitada et al, 1994; Reed et al, 1994; Keith et al, 1995).
Our clinical results are clearly in accordance with such studies.
We also analysed our results at the DNA level. No significant
difference was observed between DNA results observed during
treatment and response or overall survival. Yet a significant
freedom from progression advantage was demonstrated in favour
of patients whose circulating cells disappeared during treatment,
as expected according to Gribben’s studies (Gribben et al, 1991;
Gribben, 1994). It should be pointed out that we considered results
only obtained during treatment but not subsequent samples, since
we were searching for a predictive test available at the end of
treatment, a moment when useful therapeutic options could be
discussed. However, the quantitative analysis of these results
would be more appropriate and probably would improve the
predictive value of DNA PCR in this setting.
In conclusion, we have demonstrated a relationship between
treatment and bcl-2/IgH expression down-regulation. Furthermore,
RNA-negative conversion was significantly correlated with CR and
was associated with a lower rate of relapse or progression. These
results could be considered as a confirmation of in vitro data
showing that bcl-2 is involved in drug resistance. Finally, bcl-2/IgH
expression analysis offers new opportunities to take advantage of
the FL model while analysing the activity of the oncogene that is
specifically disregulated in tumour cells. However, whether bcl-
2/IgH expression monitoring will be of clinical value during treat-
ment of FL patients remains to be demonstrated in further
prospective studies. Finally, as new treatment strategies become
available in FL (Solal-Celigny et al, 1993; Rohatiner et al, 1994;
Freedman et al, 1996; McLaughlin et al, 1996; Bierman et al,
1997), this new tool could help to define whether these treatments
really influence the biological behaviour of FL, thus explaining
further potential clinical improvements. It could also help in the
search for new agents that might potentially alter the currently
unaffected FL natural history.
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